| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.03 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.03 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.065 | 0.03 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | indisulam | CTRPv2 | pan-cancer | AAC | 0.069 | 0.03 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.03 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.064 | 0.03 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.096 | 0.03 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.03 |